Methods
Presence of anti-JCPyV antibodies and JCPyV DNA was analyzed in 39 patients with relapsing-remitting multiple sclerosis undergoing natalizumab therapy.
Anti-JCPyV antibodies were evaluated in serum by a 2-step virus-like particle-based ELISA assay (Stratify), and JCPyV DNA was evaluated in peripheral blood mononuclear cells, plasma, and urine by quantitative PCR.
The anti-JCPyV antibodies were evaluated in serum samples collected at the same time or later than those collected for DNA analysis.
Results
JCPyV DNA was detected in 59% of patients, and anti-JCPyV antibodies were present in 67%.
JCPyV DNA occurred more often in blood than in urine.
Anti-JCPyV antibodies were observed in 70% of the JCPyV-infected patients, and JCPyV DNA was detected in 50% of the patients without anti-JCPyV antibodies.
When JCPyV DNA was investigated in blood and urine the frequency of infection was higher than previously described.
Story Source: The above story is based on materials provided by MDLINX
Note: Materials may be edited for content and length
